This article is more than 5 years old. Information may no longer be current.

B&L sales up during first quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ROCHESTER, N.Y. — Bausch & Lomb had first quarter sales of $554.3 million in 2005, an increase of 9% from first quarter sales in 2004, the company announced in a press release. B&L’s lens care category led sales growth, the company noted. Pharmaceutical sales increased 13% and cataract and vitreoretinal sales increased 6% compared with last year’s figures. Refractive sales were down by 12% from last year’s first quarter.

The growth in pharmaceuticals was helped by the U.S. launch of Zylet (loteprednol etabonate 0.5%, tobramycin 0.3% ophthalmic suspension), a combination corticosteroid-antibiotic for topical ophthalmic use, the company stated.

B&L noted “strong double-digit gains” for its SofPort and Akreos lines of foldable IOLs. Refractive surgery sales declines were attributed to lower laser equipment sales in the Americas and Europe regions, the press release said.